The True Test of Success

Developing advanced diagnostic testing for people with cancers and complex diseases can change lives. For Castle Biosciences, that culture is powering their mission.

“I think the single most remarkable aspect of our company since our inception is our exceptional people-first culture. It is the most important thing we have here at Castle.” Toby Juvenal, one of the three founders of Castle Biosciences (Nasdaq: CSTL) and the Company’s chief commercial officer, is one of the architects of this inspired approach to success. “We work to foster inclusion in a collaborative work environment to allow employees to flourish We’ve done that day-in and day-out from the beginning.”

Castle is flourishing in their quest to develop molecular diagnostics aimed at improving health by helping guide the care journey for people with cancers and other diseases. Improved care can lead to improved health for patients, and that is the North Star driving Castle forward.

Established in 2008, the company went public in 2019. Since that time, Castle has experienced profound growth. In only five years, its workforce has expanded from 135 to 700-plus people, and total revenue has increased from $51.9 million in 2019 to $220 million in 2023.

Castle was founded on the belief that the traditional approach to developing treatment plans for patients with rare cancers using clinical and pathological factors alone could be improved by incorporating personalized genomic information.

"The challenge is finding which patients are at the highest risk of their conditions progressing. That's where TissueCypher comes into play." - Toby Juvenal, Chief Commercial Officer